Global Mesothelioma Market Spotlight 2017-2026 – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Market
Spotlight: Mesothelioma” report has been added to ResearchAndMarkets.com’s
offering.

This Market Spotlight report covers the mesothelioma market, comprising
key pipeline and marketed drugs, clinical trials, upcoming and
regulatory events, patent information, a 10-year disease prevalence
forecast, and licensing and acquisition deals, as well as presenting
drug-specific revenue forecasts

Key Takeaways

• The report estimates that in 2017, there were 18,900 incident cases of
  mesothelioma in adults aged 45 years and older worldwide, and
  forecaststhat number to increase to 22,690 incident cases by 2026.
• Oceania is estimated to have the highest disease incidence (2.85 per
  100,000 males, and 0.50 per 100,000 females), while Latin America and
  the Caribbean has the lowest incidence (0.29 per 100,000 males, and
  0.17 per 100,000 females).
• The approved drugs in the mesothelioma space target thymidylate
  synthase and dihydrofolate reductase. Both of the approved drugs are
  administered via the intravenous route.
• The majority of industry-sponsored drugs in active clinical
  development for mesothelioma are in Phase II. Therapies in the
  mesothelioma space focus on a wide variety of targets. The majority of
  drugs in development for mesothelioma are administered via the
  intravenous route, with the remainder being intramuscular, oral,
  intratumoral, and subcutaneous formulations.
• High-impact upcoming events in the mesothelioma space comprise topline
  Phase III trial results for Zeltherva, and topline Phase II trial
  results for Zepsyre.
• The overall likelihood of approval of a Phase I mesothelioma asset is
  5.6%, and the average probability a drug advances from Phase III is
  33.3%. Drugs, on average, take 14.7 years from Phase I to approval,
  compared to 9.2 years in the overall oncology space.
• There were seven licensing and asset acquisition deals involving
  mesothelioma drugs during 2014-18. The $475m licensing agreement
  signed in 2017, between Calithera Biosciences and Incyte, to research,
  develop, and commercialize Calithera’s CB1158, was the largest deal
  during the period.
• The clinical trials distribution across Phase I-IV indicates that the
  vast majority of trials have been in the early and mid-phases of
  development, with 95% of trials in Phase I-II and only 5% in Phase
  III-IV.
• The US has a substantial lead in the number of mesothelioma clinical
  trials globally. The UK leads the major EU markets, while Japan has
  the top spot in Asia.
• Clinical trial activity in the mesothelioma space is dominated by
  completed trials. Eli Lilly has the highest number of completed
  clinical trials for mesothelioma, with 42 trials.
• Eli Lilly leads industry sponsors with the highest number of clinical
  trials for mesothelioma

Key Topics Covered:

OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

Subtypes

TREATMENT

Surgery

Chemotherapy

Radiotherapy

EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

RECENT EVENTS AND ANALYST OPINION

SEL-403 for Mesothelioma (October 17, 2018)

Tazemetostat for Mesothelioma (September 24, 2018)

Tazemetostat for Mesothelioma (April 23, 2018)

BAY 94-9343 for Mesothelioma (July 21, 2017)

KEY UPCOMING EVENTS

PROBABILITY OF SUCCESS

LICENSING AND ASSET ACQUISITION DEALS

PARENT PATENTS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE

Sponsors by status

Sponsors by phase

BIBLIOGRAPHY

Prescription information

APPENDIX

For more information about this report visit https://www.researchandmarkets.com/r/ndx0u4

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For
E.S.T. Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Oncology
Drugs